Key result
CRT outperforms medical therapy for functional outcomes, QoL, and mortality in HF patients.
Why the study?
Heart failure involves complex pathophysiology complicating treatment, prompting a review of the role, key points, challenges, and future implications of cardiac resynchronization therapy.
Does cardiac resynchronization therapy improve functional outcomes and reduce mortality in patients with heart failure?
Does cardiac resynchronization therapy improve functional outcomes and reduce mortality in patients with heart failure?
This narrative review reaffirms the efficacy of CRT in improving functional outcomes, quality of life, and mortality in appropriately selected heart failure patients.
Supports CRT consideration in selected HF patients; confirms prior evidence yet leaves optimal selection open for prospective trials.
Introduction: Structural and functional cardiac defects leading to inadequate tissue oxygenation is known as Heart failure (HF) which is characterized by extensive morbidity and mortality. Pathophysiology of HF involves systolic and diastolic dysfunction, neurohormonal dysregulation, and imbalance in inflammatory mediators which complicates treatment further. Cardiac resynchronization therapy (CRT) is an approach used for restoring ventricular synchrony and enhancing mechanical efficiency. This study discusses various key points of CRT and its uses in HF and discusses challenges and future implications. Methods: An extensive review of the literature was conducted with evidence from several databases like Medline, PubMed Central, and Embase. Preference was given to articles published after 2010, but relevant articles even pre-2010 were included. Mendeley was used as a reference manager for formatting. Results: Functional improvements and an enhanced quality of life across a diverse range of patients have been demonstrated using CRT. This has significantly impacted the mortality rates of patients with HF. This manuscript conducted a comparative analysis various hallmark clinical trials conducted in lieu of CRT, across many years (2002, 2003, 2004, 2005, 2017, 2018, 2020). All trials have noted the supremacy of CRT compared to pharmaceutical treatment or other therapeutic methods. Majority of the trial participants had an LVEF of ≤ 35%, a QRS duration of ≤ 150 ms, and were categorized as NYHA class II-IV before initiation of CRT and, posttreatment, LVEF was improved significantly. The main advantages noted were functional improvements, such as enhanced quality of life and reduced mortality. Conclusion: There have been multiple efforts undertaken to address the challenges in CRT, which include a reduction in the rates of nonresponding patients and using alternative adjunctive therapies like defibrillators. These have been shown to improve outcomes among HF patients. Although CRT is noted to be very efficient, some challenges like technological limitations, uncertainty regarding optimal pacing, and nonresponding patients, exist. Ongoing research aims to further develop and revolutionize HF care and improve patient outcomes across the world by refining patient selections and CRT efficacy.
No takes yet. Share an insight, caveat, or question.
Uwishema et al. (2024) conducted a review in Heart failure. Cardiac resynchronization therapy (CRT) vs. Pharmaceutical treatment or other therapeutic methods was evaluated on Functional improvements, quality of life, and mortality. Cardiac resynchronization therapy demonstrated supremacy over pharmaceutical treatment in improving functional outcomes, quality of life, and mortality among heart failure patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: